Agranulocytosis
Symptoms, Doctors, Treatments, Advances & More

Save information for later
Sign Up

Learn About Agranulocytosis

Condition 101 content is not available at this time, but we are continually updating the site. Please check back.

However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.

Who are the top Agranulocytosis Local Doctors?
Elite in Agranulocytosis
Hematology Oncology | Hematology | Oncology
Elite in Agranulocytosis
Hematology Oncology | Hematology | Oncology

Duke Cancer Center

20 Duke Medicine Cir, 
Durham, NC 
Experience:
52+ years
Languages Spoken:
English
Offers Telehealth

When someone is faced with a diagnosis of lung cancer, they may be going through surgery, radiation treatment, chemotherapy or enrolling in a clinical trial. It’s a very complicated process to understand what’s involved and what may happen next. It’s also hard to hear all the answers if you’re by yourself. We encourage our patients to come with family members and friends and loved ones and particularly to identify one or two main go-to people in terms of care-giving and support. That way we can engage them in the whole process. Just as we have a team taking care of the patient, the patient has a team, too. At Duke, we have the opportunity to engage patients in the very latest treatment approaches, whether it’s a new surgical technique, the latest radiation approach, or some novel chemotherapy, immunology, or targeted therapy, several of which we’ve been developing. Duke provides patients with a real opportunity that they may not have elsewhere. Dr. Crawford is rated as an Elite provider by MediFind in the treatment of Agranulocytosis. He is also highly rated in 26 other conditions, according to our data. His clinical expertise encompasses Febrile Neutropenia, Agranulocytosis, Lung Cancer, and Non-Small Cell Lung Cancer (NSCLC). Dr. Crawford is board certified in American Board Of Internal Med, Hematology/Oncology , American Board Of Internal Med, Internal Medicine , and American Board Of Internal Med, Medical Oncology.

Elite in Agranulocytosis
Hematology
Elite in Agranulocytosis
Hematology

Fred Hutchinson Cancer Center

1100 Fairview Ave N, 
Seattle, WA 
Languages Spoken:
English

Gary Lyman is a Hematologist practicing medicine in Seattle, Washington. Dr. Lyman is rated as an Elite provider by MediFind in the treatment of Agranulocytosis. He is also highly rated in 6 other conditions, according to our data. His clinical expertise encompasses Febrile Neutropenia, Agranulocytosis, Venous Thromboembolism (VTE), and Breast Cancer.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Agranulocytosis
Elite in Agranulocytosis
Genolier, VD, CH 

Matti Aapro practices practicing medicine in Genolier, Switzerland. Aapro is rated as an Elite expert by MediFind in the treatment of Agranulocytosis. They are also highly rated in 8 other conditions, according to our data. Their clinical expertise encompasses Febrile Neutropenia, Agranulocytosis, Breast Cancer, and HER2 Negative Breast Cancer.

What are the latest Agranulocytosis Clinical Trials?
Prospective Evaluation of Xerava™ (Eravacycline) Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia

Summary: Antibacterial prophylaxis is recommended in patients at high risk of infection, specifically patients undergoing acute leukemia induction therapy or hematopoietic stem cell transplant (HSCT) who are expected to have profound neutropenia (ANC\<100 neutrophils/milliliter) for more than seven days. Xerava™ (eravacycline) has a broad spectrum of activity including many multi-drug resistant strains of ...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Prospective, Single-arm Phase II Trial of Trilaciclib Administered Prior to Sacituzumab Tirumotecan in Patients With EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors(PROTECT-2)

Summary: This study is a prospective, single arm phase II clinical trial aimed at patients with advanced non-small cell lung cancer resistant to EGFR-TKI. The aim is to evaluate the efficacy and safety of trilaciclib in bone marrow protection before monotherapy with sacituzumab tirumotecan. Patients with advanced non-small cell lung cancer resistant to EGFR-TKI, after signing informed consent, will be scre...